 |
|
| VARUN GUPTA, M.D. |
| |
Office: |
Desert Cancer Care, Inc.
39000 Bob Hope Dr.,
Eisenhower Medical Center
Uihlein Bldg., Ste. 201
Rancho Mirage, CA 92270 |
| |
Affiliating Institutions : |
Eisenhower Medical Center
39000 Bob Hope Dr.,
Rancho Mirage, CA 92270 |
| |
Education: |
|
| |
MBBS:
1987-1992 |
Medical School and Internship
Dayanand Medical College and Hospital
Punjab University, India |
| |
MD:
1994-1997 |
Internal Medicine Residency
Long Island College Hospital
State University of New York |
| |
Fellowship:
1994-1997 |
Medical Oncology Fellowship
North Shore University Hospital
NYU School of Medicine |
| |
Board Certification: |
Diplomate Medical Oncology, American Board of Internal Medicine |
|
|
|
| |
Interests: |
Particular interest in Lung, Prostate Cancers and GI Cancers. |
| |
Positions and Appointments: |
|
| |
2005 - Current |
Desert Cancer Care, Inc.
Uihlein Bldg, #201
Eisenhower Medical Center Campus
39700 Bob Hope Drive
Rancho Mirage, CA 92270 |
| |
2004 - 2005 |
Cancer and Blood Institute of the Desert,
Rancho Mirage, CA 92270 |
| |
2000 - 2004 |
Medical Oncology
Morongo Medical Group
|
| |
Licenses: |
California
South Carolina
Florida |
| |
Honors and Awards: |
. Chair, Section of Oncology
Eisenhower Medical Center
. Chief Fellow, Hematology/Oncology
North Shore Hospital, NY
. Assistant Chief Resident
Department of Medicine
Long Island College Hospital, NY
. Awarded Best Graduating Resident
Department of Medicine
Long Island College Hospital, NY
. National Scholarship through Medical School |
| |
Memberships: |
. American College of Physicians
. American Society of Clinical Oncology |
| |
Publications: |
|
| |
- Radiation therapy in cancer patients 80 years of age and older Am J Clin Oncol 2000 Oct; 23(5): 526-30
- Liver dysfunction after high-dose chemotherapy and role of histologic diagnosis Poster presented at ASCO 2000.
- Novel chemotherapy agents, The Chemotherapy Source Book, editor M. Perry, 2001.
- Letter to Editors: Harrison’s Principles of Internal Medicine. Comment on CDC Classification of AIDS
|
| |
Research Experience: |
|
| |
ASCO 2010 Meeting |
A phase ll study of a modified pegylated liposomal doxorubicin (PLD), bortezomid, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM). |
2008 |
Sub-Investigator - Novartis Pharmaceuticals Corp: A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and safety of Zometa in patients with documented bone metastases from Breast cancer. Protocol #CZOL446E2352 |
2008 |
Principal-Investigator - Amgen Protocol# 20050154: Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell
Lung Cancer Already Receiving Gemcitabine and Platinum. |
2008 |
Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04 Expanded Access Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy. |
2008 |
Principal-Investigator for Millennium Pharma., : Protocol # C05009:
Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation. Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD)
Vs. Velcade, Melphalan, and Prednisone (VMP). |
2008 |
Sub-Investigator – NSABP-B-42: A Clinical Trial to Determine the Efficacy o Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Follow by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. |
2008 | |
